Allspring Global Investments
CTMX icon

Allspring Global Investments’s CytomX Therapeutics CTMX Stock Holding History

Allspring Global Investments’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-87,671
Closed -$234K – 2740
2022
Q1 		$234K Sell
87,671
-3,175
-3% -$12.2K ﹤0.01% 2522
2021
Q4 		$393K Buy
+90,846
New +$532K ﹤0.01% 2395

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allspring Global Investments's CTMX Position: Q2 2022 in Review

Allspring Global Investments sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 87,671 shares — an estimated $234K sold.

Allspring Global Investments first reported a position in CTMX in Q4 2021 and held it in 2 quarters. The position peaked at $393K in Q4 2021. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Allspring Global Investments reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 87,671 CytomX Therapeutics shares in Q2 2022, an estimated $234K.
  • Allspring Global Investments first reported a position in CytomX Therapeutics in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's CytomX Therapeutics position peaked at $393K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.